Collegium Pharmaceutical, Inc. (COLL)
NASDAQ: COLL · IEX Real-Time Price · USD
32.47
-1.20 (-3.56%)
May 17, 2024, 4:00 PM EDT - Market closed

Company Description

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.

The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003.

Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical logo
Country United States
IPO Date May 7, 2015
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 197
CEO Joseph J. Ciaffoni

Contact Details

Address:
100 Technology Center Drive
Stoughton, Massachusetts 02072
United States
Phone 781-713-3699
Website collegiumpharma.com

Stock Details

Ticker Symbol COLL
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001267565
CUSIP Number 19459J104
ISIN Number US19459J1043
SIC Code 2834

Key Executives

Name Position
Michael Thomas Heffernan B.S. Pharm, R.Ph. Co-Founder and Independent Chairman
Joseph J. Ciaffoni President, Chief Executive Officer and Director
Colleen Tupper Executive Vice President and Chief Financial Officer
Shirley R. Kuhlmann Executive Vice President, General Counsel, Chief Administrative Officer and Secretary
Scott Dreyer Executive Vice President and Chief Commercial Officer
Dr. Thomas B. Smith FAAFP, M.D. Executive Vice President and Chief Medical Officer
Dr. Christopher Shayne James M.D. Vice President of Investor Relations
Bart J. Dunn Executive Vice President of Strategy and Corporate Development
Scott Sudduth Head of Technical Operations

Latest SEC Filings

Date Type Title
May 14, 2024 144 Filing
May 13, 2024 8-K Current Report
May 10, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
May 10, 2024 8-K Current Report
May 9, 2024 10-Q Quarterly Report
May 9, 2024 8-K Current Report
Apr 29, 2024 8-K Current Report
Apr 11, 2024 8-K Current Report
Apr 5, 2024 ARS Filing
Apr 5, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material